REC-164067

REC-164067 is a **preclinical small-molecule investigational drug** developed by **Recursion Pharmaceuticals** in its *Clostridium difficile* colitis program. Publicly available company disclosures identify it as one of several orally active, gut-biased lead compounds designed to inhibit the **glucosyltransferase activity of *C. difficile* toxins**, while third-party pipeline databases also describe it as a **UGCG inhibitor**. Because the exact target assignment and final development candidate selection have not been fully detailed in primary public disclosures, the most defensible characterization is that REC-164067 is an early-stage anti-infective small molecule intended for *C. difficile* infection or colitis, with development reported at the **preclinical** stage.